H.C. Wainwright Maintains Precision BioSciences(DTIL.US) With Buy Rating, Maintains Target Price $60
HC Wainwright & Co. Reiterates Buy on Precision BioSciences, Maintains $60 Price Target
Precision BioSciences Analyst Ratings
Buy Rating on Precision BioSciences Highlighted by Promising Gene Editing Pipeline and Potential Hepatitis B Cure
JonesTrading Maintains Precision BioSciences(DTIL.US) With Buy Rating, Maintains Target Price $30
Precision BioSciences Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Precision BioSciences, Maintains $60 Price Target
HC Wainwright & Co. : The Precision BioSciences (DTIL.US) rating was reaffirmed, adjusted from buy to buy rating, and the target price was adjusted from $60.00 to $60.00.
Buy Rating on Precision BioSciences: Leading the Way in Gene Editing for Chronic Hepatitis B
Buy Rating Affirmed for Precision BioSciences on Strong Pipeline and Market Potential
HC Wainwright & Co. : Reiterated Precision BioSciences (DTIL.US) rating, adjusted from buy to buy rating, target price of $60.00.
Precision BioSciences Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Precision BioSciences (DTIL) and Adicet Bio (ACET)
Maintaining Hold on Precision BioSciences Pending Clinical Data and Strategic Reassessments
Buy Rating Affirmed for Precision BioSciences on Advancing Gene Editing Pipeline and Strong Financials
Precision BioSciences Analyst Ratings
Precision BioSciences Analyst Ratings
Buy Rating Affirmed for Precision BioSciences Amid Strong Gene Editing Prospects and Upcoming Milestones
BMO Capital Reaffirms Their Hold Rating on Precision BioSciences (DTIL)
Buy Rating Affirmed for Precision BioSciences on Promising Gene Editing Prospects and Strong Financials